i-base

News

Hepatitis C for people living with HIV (April 2017)

What is hepatitis C? Testing, diagnosis and monitoring. New treatment and drugs in development. Deciding whether to treat or wait. Sexual transmission and safer HCV sex.

March/April HTB now online

Reports from 23rd BHIVA conference on sexual health in the UK, and paediatric and cure-related research from CROI 2017… plus new i-Base appeal…

Side effects – pocket guide (2017)

Pocket side effects guide is a small i-Base leaflet about side effects, long term health and your quality of life (QoL) Pocket side effects guide online Download pocket side effects PDF Order free printed copies Full guide to HIV and your quality …

PrEP – a pocket guide (2017)

Pocket PrEP is an A7-sized guide to PrEP in the UK. It is an introduction to how PrEP works and buying PrEP online. Download pocket PrEP – PDF (400 Kb) Order free printed copies More pocket ART pages PrEP stands for pre-exposure prophylaxis. It is …

Pocket ART guide (2017)

Pocket ART is an A7-sized guide to HIV treatment (ART). It is an easy introduction to HIV treatment. Pocket ART guide online Pocket ART guide PDF download Order a free printed copy ART stands for antiretroviral treatment. HIV drugs are …

Hepatitis C – pocket guide (2017)

Pocket hepatitis C (HCV) guide is a small i-Base leaflet about HCV for people who are also HIV positive. It covers testing, monitoring and treatment – especially with new HCV meds called DAAs (direct acting antivirals). Download pocket HCV – PDF (400 Kb) Order …

January/February HTB now online

14 rapid reports from CROI 2017, plus journal reviews and sexual health in the UK – including drop in HIV diagnoses, PrEP news, and HPV vaccines…

Pocket guides (March 2017)

NEW: pocket size leaflets based the longer i-Base guides – includes hepatitis C confection and UK guide to PrEP

Fit for purpose: antiretroviral treatment optimisation (Feb 2017)

Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones. These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects. The ARVs are: dolutegravir (DTG), tenofovir alafenamide …

Early reports from CROI 2017

14 rapid reports from Seattle… new drugs, dolutegravir monotherapy studies stopped, paediatric formulations, PrEP failure case, good news from brain scans… more to follow…

November/December HTB now online

Post-US election issue: reports from Glasgow Congress and Research for Preventions meetings, global treatment, EACS guidelines, UK PrEP updates and more…

New: UK guide to PrEP (November 2016)

Using generic PrEP bought online – new guide for how to use PrEP safely, including options for dosing…

International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

Introduction This year the biennial Glasgow conference was held from 23-26 October 2016. The meeting has a single-track programme making it easy to attend and follow the whole programme, often highlight important European research before it is presented at CROI, …

HIV Research for Prevention Conference (HIVR4P) 2016

First reports from this prevention conference being held in Chicago.

September/October HTB now online

PrEP safety, side effects of integrase inhibitors, HIV and children and global access to dolutegravir – reports from four meetings + other news including reduced dose maintenance studies…

July/August HTB now online

News from Durban on HIV prevention including TasP and PrEP, paediatrics, TB and cure research – plus news about PrEP in the UK…

Reports from AIDS 2016 and linked workshops

Reports from AIDS 2016 include PrEP and new drugs plus news from the pre-conference paediatric and TB workshops…

PROUD study closes leaving participants with no access to PrEP

Simon Collins, HIV i-Base On 29 July 2016, the PROUD study website announced that the study will close without being able to continue to provide participants with oral PrEP. [1] The press release blames NHS England for cancelling the previous …

CERO: No se registró ningún caso de transmisión del VIH vinculado a la pareja en el estudio PARTNER, tras 58.000 relaciones sexuales sin usar condón

Simon Collins, VIH i-Base Los resultados del estudio PARTNER publicados en coincidencia con la conferencia AIDS 2016, que se inaugura en Durban (Sudáfrica) la próxima semana, revelan el impacto del tratamiento antirretroviral en la drástica reducción de la transmisión del …

Preguntas y Respuestas sobre el estudio PARTNER: Cómo interpretar el resultado de cero transmisiones

El siguiente cuestionario está relacionado con el estudio PARTNER que fue publicado en la edición del 12 de julio de 2016 de Journal of the American Medical Association (JAMA), cuya versión completa está disponible de forma gratuita. A continuación se …

Post navigation